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ABSTRACT
Introduction: The goal of treatment in diabetes
is to control hyperglycemia to near-normal
glucose levels, which is important to prevent
the progression of microvascular and
macrovascular complications. Mitiglinide is
a rapid- and short-acting insulinotropic
sulfonylurea receptor ligand that is known to
improve postprandial hyperglycemia in patients
with type 2 diabetes. The aim of this study was
to investigate the long-term efficacy and safety
of mitiglinide in Japanese type 2 diabetic
patients inadequately controlled by dipeptidyl
peptidase-4 (DPP-4) inhibitor or biguanide
monotherapy.
Methods: In patients with type 2 diabetes
mellitus (T2DM) receiving a stable
monotherapy regimen with a DPP-4 inhibitor
or biguanide added to dietary therapy, an
additional 10 mg mitiglinide was administered
for 52 weeks. The efficacy end points were
postprandial plasma glucose (PPG) (30 min,
1 h, 2 h), postprandial insulin (30 min, 1 h,
2 h), insulinogenic index, 1,5-anhydroglucitol
(1,5-AG), glycated hemoglobin (HbA1c), and
fasting plasma glucose. The safety end points
included the incidence and types of adverse
events and adverse drug reactions.
Results: A total of 136 patients with T2DM
were eligible for enrollment in this study and
received mitiglinide. The average HbA1c before
the start of mitiglinide administration
(baseline) was 7.47% in the DPP-4 inhibitor
combined treatment group (DPP-4 inhibitor
CTG) and 7.50% in the biguanide combined
treatment group (biguanide CTG), and the 2 h
PPG was 248.1 and 243.3 mg/dL, respectively.
Following the addition of mitiglinide to the
treatment regimen for 52 weeks, the early
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postprandial decrease in insulin secretion
improved and PPG improved in both the DPP-
4 inhibitor CTG and biguanide CTG. At final
evaluation, the HbA1c \7.0% achievement rate
was 57.4% in the DPP-4 inhibitor CTG and
29.2% in the biguanide CTG. The incidence of
hypoglycemia in the DPP-4 inhibitor CTG and
biguanide CTG was 3.0% (2/67 patients) and
2.9% (2/69 patients), respectively. The
hypoglycemic symptoms were mild in all cases.
Conclusion: Combination therapy with
mitiglinide and DPP-4 inhibitors or biguanides
improved glycemic control over the long term
without increasing risks to safety due to events
such as hypoglycemia, and this is a clinically
promising therapeutic strategy in T2DM.
Keywords: Biguanide; Combination therapy;
DPP-4 inhibitor; HbA1c; Mitiglinide;
Postprandial; Type 2 diabetes
INTRODUCTION
Diabetes mellitus is characterized by chronic
hyperglycemia and other metabolic
abnormalities due to insufficient action of
insulin. Diabetes is classified as type 1 diabetes
mellitus (T1DM) or type 2 diabetes mellitus
(T2DM) based on its etiology. The pathogenesis
of T2DM involves a combination of impaired
insulin secretion from pancreatic b cells and
insulin resistance. Hyperglycemia develops
from this insulin-insufficient state, often
presenting early as postprandial hyperglycemia.
The goal of treatment in diabetes is to
control hyperglycemia to near-normal glucose
levels. This is important to prevent progression
to microvascular complications, as well as
to macrovascular complications such as
myocardial infarction. Postprandial
hyperglycemia has recently been reported to
be an independent risk factor for arteriosclerotic
disease [1]. The Diabetes Epidemiology:
Collaborative analysis of Diagnostic criteria in
Europe (DECODE) study reported a positive
correlation between 2 h values on an oral
glucose tolerance test (OGTT) and overall
mortality rates [2]. The Funagata study,
conducted among residents of Funagata in
Yamagata Prefecture, reported that impaired
fasting glucose (IFG), defined as an elevation
of fasting plasma glucose (FPG), but with a
normal 2 h OGTT value, was not a risk factor for
cardiovascular death [3]. Large-scale clinical
studies, including the Action in Diabetes and
Vascular Disease: Preterax and Diamicron MR
Controlled Evaluation (ADVANCE) study [4],
the Action to Control Cardiovascular Risk in
Diabetes (ACCORD) study [5] and the Veterans
Affairs Diabetes Trial (VADT) [6], showed that
glycemic control based on glycated hemoglobin
(HbA1c) levels alone does not reduce
macrovascular disease. In addition to glycemic
control using HbA1c as a marker, high-quality
glycemic control focusing also on postprandial
plasma glucose (PPG) levels is necessary.
Mitiglinide is a rapid- and short-acting
insulinotropic sulfonylurea receptor (SUR)
ligand, a benzylsuccinic acid derivative [7–9],
which improves postprandial hyperglycemia in
particular. In addition to mitiglinide,
repaglinide and nateglinide are currently in
clinical use as insulinotropic SUR ligands.
The present study evaluated the long-term
efficacy and safety of adding mitiglinide
(mitiglinide calcium hydrate (Glufast tablets;
Kissei Pharmaceutical Co. Ltd; Matsumoto,
Japan) in Japanese patients with diabetes
inadequately controlled with a dipeptidyl
peptidase-4 (DPP-4) inhibitor or biguanide
monotherapy.
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MATERIALS AND METHODS
This study was conducted between March 2011
and August 2012 at 13 medical institutions in
Japan. All procedures were in accordance with
the ethical standards of the responsible
committee on human experimentation and
with the Helsinki Declaration of 1975, as
revised in 2000. Informed consent was
obtained from all patients before inclusion
into the study.
Patients
Subjects were adult T2DM patients without
adequate glycemic control. Inclusion criteria
were: HbA1c 6.9% to \9.4%; 1 or 2 h PPG
C200 mg/dL on a meal tolerance test; and a
fixed dosage and administration of either a DPP-
4 inhibitor or biguanide during at least 8 weeks
before starting mitiglinide. Exclusion criteria
were: patients with history of treatment with
high-dose sulfonylurea (SU) within 24 weeks
(168 days) of starting the observation period
(week 4); patients requiring insulin therapy;
patients with severe diabetic complications
(including neuropathy, retinopathy, and
nephropathy), severe liver disease, renal
dysfunction, hypertension, or heart disease.
Study Design
This study was a multicenter, open label, long-
term clinical trial. Patient eligibility was
assessed during a 4-week observation period.
Patients were seen as outpatients every 4 weeks
after starting the study, and treatment was
continued for 52 weeks.
During the 4-week observation period, a
fixed dose of DPP-4 inhibitor or biguanide was
administered orally. Eligible patients who met
the inclusion criteria during the observation
period then continued with the DPP-4 inhibitor
or biguanide at the same dosage and
additionally received mitiglinide 10 mg three
times a day orally (t.i.d PO) immediately
(within 5 min) before each meal. Thereafter, if
after 12 weeks of continuous administration
HbA1c did not reach the target value [\7.4% if
C7.4% at the start of administration (week 0) or
\6.9% if \7.4% at week 0], the dosage of
mitiglinide could be increased to 20 mg t.i.d
from week 16 to attempt to gain further
improvement. However, if the physician
judged that mitiglinide 10 mg t.i.d presented a
safety problem, it could be reduced to 5 mg
t.i.d.
During both the observation and treatment
periods, concomitant use of oral hypoglycemic
agents (other than the study drug) and the use
of insulin products were prohibited, whereas
administration and dosage of drugs used from
before the study for treatment of mild-to-
moderate complications was not changed
whenever possible.
Patient characteristics were examined
at screening (week 4). HbA1c, FPG, 1,5-
anhydroglucitol (1,5-AG), hematology, blood
chemistry and urinalysis values, body weight,
and blood pressure were assessed every 4 weeks
from week 4 to week 52. Postprandial plasma
glucose and postprandial insulin (30 min, 1 h,
and 2 h after meal) were measured at weeks 4,
16, 28, and 52. The 400-kcal meal tolerance
test at week 4 was performed following
administration of a DPP-4 inhibitor or
biguanide, and from after week 16 by that of a
DPP-4 inhibitor, or biguanide, in combination
with mitiglinide.
Study End Points
Efficacy end points included: change in HbA1c,
1,5-AG, and FPG at each evaluation point from
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that measured at week 4 after addition of
mitiglinide; therapeutic achievement rate of
HbA1c target; and changes in postprandial
plasma glucose or postprandial insulin level.
Safety end points were incidence rates of
adverse events including hypoglycemic
episodes and adverse drug reactions. Weight
and blood pressure were measured every
4 weeks throughout the study period.
Target Sample Size
The number of patients recruited was based on
the ‘‘Guidelines for Clinical Evaluation of Oral
Hypoglycemic Agents’’ published by the
Ministry of Health, Labour and Welfare
(MHLW) in 2010 [10]. The target sample size
to evaluate 52 weeks of therapy in each baseline
drug combined treatment group was set at C50
patients (a total C100 patients across the study).
Statistical Analysis
Efficacy end points included PPG (30 min, 1 h,
2 h), postprandial insulin (30 min, 1 h, 2 h),
HbA1c, FPG, 1,5-AG, and fasting insulin. For
these end points, mean and standard deviation
(SD) of the changes at each evaluation time
point (value at each evaluation time
point - value at baseline) were calculated.
Changes over time are shown and compared
with baseline using the one-sample t test. The
HbA1c target achievement rate was evaluated at
weeks 12, 28, 40, 52, and/or final evaluation.
The HbA1c target achievement rate was
calculated as the percentage of patients who
achieved an HbA1c of \7.0% at weeks 12, 28,
40, 52, and/or final evaluation among patients
with an HbA1c C7.0% at week 0. The
insulinogenic index is shown as the median
value at each evaluation time point. Safety end
points included adverse events and adverse drug
reactions (all and hypoglycemia), clinical
laboratory tests and physiological parameters.
The presence or absence of adverse events and
adverse drug reactions (all and hypoglycemia)
was assessed in each patient, and the incidence
and two-sided 95% confidence intervals were
calculated. The incidence and types of adverse
events and adverse drug reactions overall and
by organ system class were calculated. Totals




Figure 1 shows the patient characteristics. A
total of 191 patients consented to study
participation. After a 4-week observation
period with administration of DPP-4 inhibitors
or biguanides as the baseline drug, mitiglinide
was administered to 136 patients who were
judged as being eligible for the study (DPP-4
inhibitor CTG, 67 patients; biguanide CTG, 69
patients). Baseline drugs included sitagliptin in
26 patients, vildagliptin in 18, alogliptin in 23,
metformin in 66, and buformin in 3.
Treatment was discontinued in 26 patients
(DPP-4 inhibitor CTG, 9; biguanide CTG, 17)
during the study. The reasons for
discontinuation from the study were as
follows: for DPP-4 inhibitor CTG—adverse
events in two patients, inadequate response in
five, and other reason in three patients (‘‘at
request of patient,’’ ‘‘needed to discontinue
baseline drug,’’ and ‘‘could not return for
outpatient visit’’); and for biguanide CTG—
adverse events were reported in 4 patients,
inadequate response in 12, and other reason in
2 patients (‘‘at request by patient’’ in both). One
patient in both of the DPP-4 inhibitor CTG and
biguanide CTG had two reasons for
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discontinuation (adverse event and patient
request).
Patient Characteristics
A total of 136 patients received mitiglinide
(DPP-4 inhibitor CTG, 67; biguanide CTG, 69),
but after mitiglinide was started, one patient in
the biguanide CTG was excluded because of
early discontinuation and no evaluable HbA1c.
Therefore, the full analysis set included 135
patients (DPP-4 inhibitor CTG, 67; biguanide
CTG, 68). Table 1 shows the patient
characteristics.
Baseline values (mean ± SD) for the primary
efficacy end points of HbA1c, FPG, and 2 h PPG
Fig. 1 Patient characteristics. D group DPP-4 inhibitor combined treatment group, B group biguanide combined treatment
group
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were: DPP-4 inhibitor CTG 7.47 ± 0.54%,
153.7 ± 27.1 mg/dL, and 248.1 ± 45.9 mg/dL,
respectively; and biguanide CTG 7.50 ± 0.66%,
143.8 ± 27.0 mg/dL, and 243.3 ± 53.0 mg/dL,
respectively. These patients with type 2
diabetes in the DPP-4 inhibitor CTG and
biguanide CTG had inadequate glycemic
control and were enrolled in the study. BMI
distribution before starting treatment (baseline)
showed a higher percentage of obese patients
(BMI C25 kg/m2) in the biguanide CTG than in
the DPP-4 inhibitor CTG (DPP-4 inhibitor CTG,
31.3%; biguanide CTG, 48.5%).
Efficacy
In both the DPP-4 inhibitor CTG and the
biguanide CTG, a comparison of 30 min, 1 h,
and 2 h PPG values between baseline and each
evaluation time point (weeks 16, 28 and 52, and
final evaluation) showed significant
improvement (all with P\0.001, Table 2). In
addition, FPG during early combined treatment
(weeks 12–20) showed a significant
improvement compared with baseline.
Subsequently, in both cohorts there was a
deterioration, followed by a trend toward
improvement from week 40 until completion
of mitiglinide administration (data not shown).
In both the DPP-4 inhibitor CTG and
biguanide CTG, postprandial insulin levels at
each evaluation time point confirmed
significant stimulation of insulin secretion at
30 min and 1 h postprandially (Fig. 2). Fasting
insulin levels did not substantially change
throughout the study period.
Table 1 Patient characteristics




Male, n (%) 96 (71.1) 46 (68.7) 50 (73.5)
Age (years) 58.6 ± 11.1 60.3 ± 10.6 56.9 ± 11.5
BMI (kg/m2) 24.85 ± 4.50 24.30 ± 4.71 25.40 ± 4.25
Duration of disease (years) 7.6 ± 5.6 6.7 ± 5.4 8.5 ± 5.8
HOMA-R 2.97 ± 2.86 2.95 ± 3.10 3.00 ± 2.62
HbA1c at 0 weeks (%) 7.49 ± 0.60 7.47 ± 0.54 7.50 ± 0.66
FPG at 0 weeks (mg/dL) 148.7 ± 27.4 153.7 ± 27.1 143.8 ± 27.0
PPG 30 min at -4 weeks (mg/dL) 228.1 ± 37.6 229.2 ± 36.9 227.1 ± 38.6
PPG 1 h at -4 weeks (mg/dL) 268.7 ± 39.7 269.2 ± 39.4 268.2 ± 40.3
PPG 2 h at -4 weeks (mg/dL) 245.6 ± 49.5 248.1 ± 45.9 243.3 ± 53.0
Fasting insulin at 0 weeks (lU/mL) 7.90 ± 6.68 7.49 ± 6.55 8.32 ± 6.82
Postprandial insulin 30 min at -4 weeks (lU/mL) 21.66 ± 13.84 20.08 ± 11.73 23.22 ± 15.58
Postprandial insulin 1 h at -4 weeks (lU/mL) 31.78 ± 21.86 28.73 ± 18.22 34.79 ± 24.71
Postprandial insulin 2 h at -4 weeks (lU/mL) 32.14 ± 21.65 29.73 ± 20.25 34.52 ± 22.85
Values are mean ± SD
BMI body mass index, FPG fasting plasma glucose, Hb1Ac glycated hemoglobin, HOMA-R homeostasis model assessment
ratio, PPG postprandial plasma glucose
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Figure 3 shows the changes in the
insulinogenic index in the DPP-4 inhibitor CTG
and biguanide CTG. The insulinogenic index
(IGI) at week 4 (when patients were treated with a
DPP-4 inhibitor or biguanide as monotherapy)
was low at 0.17 and 0.15 (median values),
respectively. After combined treatment with
mitiglinide (at final evaluation), the IGI was
0.59 in the DPP-4 inhibitor CTG and 0.47 in the
biguanide CTG. The addition of mitiglinide
improved early insulin secretion. In both the
DPP-4 inhibitor CTG and biguanide CTG, 1,5-AG
was significantly improved at all evaluation time
points as compared to baseline (data not shown).
Table 3 shows the changes in HbA1c. Table 4
shows the HbA1c \7.0% achievement rates at
Table 2 Change in postprandial plasma glucose
Item Baseline drug Time Number Change SD P value
PPG 30 min (mg/dL) DPP-4 inhibitors 16 weeks 65 -38.5 34.9 \0.001
28 weeks 64 -28.0 32.9 \0.001
52 weeks 58 -37.9 33.4 \0.001
Final 65 -34.8 35.5 \0.001
Biguanides 16 weeks 67 -28.0 37.2 \0.001
28 weeks 65 -23.0 46.2 \0.001
52 weeks 53 -27.6 39.1 \0.001
Final 68 -22.4 39.2 \0.001
PPG 1 h (mg/dL) DPP-4 inhibitors 16 weeks 65 -51.4 39.8 \0.001
28 weeks 64 -45.4 40.0 \0.001
52 weeks 58 -49.7 37.0 \0.001
Final 65 -46.6 38.7 \0.001
Biguanides 16 weeks 67 -42.3 38.1 \0.001
28 weeks 65 -40.0 48.4 \0.001
52 weeks 53 -37.1 44.7 \0.001
Final 68 -33.0 44.2 \0.001
PPG 2 h (mg/dL) DPP-4 inhibitors 16 weeks 65 -51.8 50.7 \0.001
28 weeks 64 -50.5 51.9 \0.001
52 weeks 58 -49.2 46.7 \0.001
Final 65 -46.3 47.0 \0.001
Biguanides 16 weeks 67 -42.3 46.7 \0.001
28 weeks 65 -42.3 56.2 \0.001
52 weeks 53 -39.1 53.5 \0.001
Final 68 -36.0 51.6 \0.001
P value: one-sided t test [vs. before treatment with mitiglinide (-4 weeks)]
DPP-4 dipeptidyl peptidase-4, PPG postprandial plasma glucose
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weeks 12, 28, 40 and 52, and at final evaluation.
HbA1c levels, compared to baseline, were
significantly lower at all evaluation time
points in the DPP-4 inhibitor CTG and were
significantly lower at all evaluation time points,
except week 40 and final evaluation, in the
Fig. 2 Change in postprandial insulin secretion (mean ± SD). a DPP-4 inhibitor combined treatment group, b biguanide
combined treatment group *P\0.05 vs. -4 weeks
Fig. 3 Insulinogenic index (median value). Insulinogenic index: D insulin (30 min - 0 min)/D glucose (30 min - 0 min).
a DPP-4 inhibitor combined treatment group, b biguanide combined treatment group
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biguanide CTG. The HbA1c\7.0% achievement
rate throughout the study period was
41.7–62.2% in the DPP-4 inhibitor CTG and
27.9–43.8% in the biguanide CTG.
Safety
Table 5 shows the incidence of adverse events
and adverse drug reactions, including
hypoglycemia. The incidence of adverse events
was 71.6% (48/67 patients) in the DPP-4
inhibitor CTG and 82.6% (57/69 patients) in
the biguanide CTG. Among adverse events, the
incidence of hypoglycemia (adverse events) was
3.0% (2/67 patients) in the DPP-4 inhibitor CTG
and 2.9% (2/69 patients) in the biguanide CTG.
Table 3 Changes in HbA1c
Time Mitiglinide/DPP-4 inhibitors Mitiglinide/biguanides
Number Change SD P value Number Change SD P value
4 weeks 67 -0.31 0.29 \0.001 68 -0.23 0.26 \0.001
8 weeks 66 -0.55 0.37 \0.001 68 -0.39 0.41 \0.001
12 weeks 66 -0.60 0.46 \0.001 68 -0.41 0.55 \0.001
16 weeks 65 -0.54 0.49 \0.001 67 -0.40 0.49 \0.001
20 weeks 65 -0.56 0.56 \0.001 67 -0.44 0.57 \0.001
24 weeks 64 -0.58 0.60 \0.001 65 -0.44 0.59 \0.001
28 weeks 64 -0.47 0.55 \0.001 65 -0.34 0.60 \0.001
32 weeks 63 -0.46 0.56 \0.001 63 -0.27 0.64 0.001
36 weeks 63 -0.34 0.59 \0.001 60 -0.19 0.59 0.015
40 weeks 61 -0.36 0.58 \0.001 60 -0.14 0.61 0.071
44 weeks 60 -0.39 0.61 \0.001 58 -0.19 0.62 0.021
48 weeks 59 -0.40 0.59 \0.001 56 -0.22 0.60 0.007
52 weeks 58 -0.45 0.69 \0.001 53 -0.28 0.63 0.001
Final 67 -0.37 0.69 \0.001 68 -0.13 0.76 0.154
Units: %
P value: one-sided t test [vs. before treatment with mitiglinide (week 0)]
DDP-4 dipeptidyl dipeptidase-4, Hb1Ac glycated hemoglobin






12 53 30 56.6
28 51 25 49.0
40 48 20 41.7
52 45 28 62.2
Final 54 31 57.4
Mitiglinide/biguanides 12 48 21 43.8
28 46 19 41.3
40 43 12 27.9
52 36 13 36.1
Final 48 14 29.2
DPP-4 dipeptidyl peptidase-4, Hb1Ac glycated hemoglobin
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Adverse drug reactions for which a causal
relationship to mitiglinide could not be
excluded occurred in 6.0% (4/67 patients) in
the DPP-4 inhibitor CTG and 5.8 % (4/69
patients) in the biguanide CTG. Hypoglycemia
in all cases was judged as an adverse drug
reaction by a physician.
Adverse events with an incidence C5% in the
DPP-4 inhibitor CTG included nasopharyngitis,
25.4% (17/67); pharyngitis, 9.0% (6/67); upper
respiratory tract infection, 7.5% (5/67);
arthralgia, 6.0% (4/67); back pain, 6.0% (4/67);
and c-glutamyltransferase increase, 6.0% (4/67).
Adverse events with an incidence C5% in the
biguanide CTG included nasopharyngitis,
43.5% (30/69); bronchitis, 11.6% (8/69);
c-glutamyltransferase increase 10.1% (7/69);
upper respiratory tract infection, 7.2% (5/69)
alanine aminotransferase increase, 7.2% (5/69);
white blood cell count increase, 7.2% (5/69);
dental caries, 5.8% (4/69); and blood urine
presence, 5.8% (4/69) (Table 6).
The number of adverse events by severity
was: DPP-4 inhibitor CTG—mild 128, moderate
5, and severe 0 events; biguanide CTG—mild
185, moderate 5, and severe 6 events. Most
adverse events were mild or moderate. A causal
relationship with mitiglinide was excluded for
all the six severe events in the biguanide CTG.
In addition, all hypoglycemic events were mild.
One serious adverse event occurred in one
patient in the DPP-4 inhibitor CTG: large
intestine carcinoma. Nine serious adverse
events occurred among five patients in the
biguanide CTG: prostate cancer, acute
myocardial infarction, brain contusion, skull
fracture, traumatic lung injury, rib fracture,
lumbar vertebral fracture, colonic polyp, and
large intestine carcinoma. A causal relationship
with mitiglinide was excluded for all of these
serious adverse events. No deaths occurred in
the study.
Figure 4 shows the changes in weight in the
DPP-4 inhibitor CTG and biguanide CTG.
Weight in the DPP-4 inhibitor CTG was: week
0, 64.62 ± 13.97 kg (mean ± SD); week 16,
65.42 ± 14.35 kg; week 28, 66.04 ± 14.64 kg;
week 40, 65.75 ± 15.12 kg, week 52,
65.17 ± 14.89 kg; and final evaluation,
65.59 ± 14.37 kg. Weight in the biguanide
CTG was: week 0, 70.23 ± 15.30 kg; week 16,
70.81 ± 15.36 kg; week 28, 70.45 ± 14.98 kg;
week 40, 71.36 ± 14.39 kg, week 52,
69.42 ± 13.52 kg; and final evaluation,
70.57 ± 15.06 kg. Weight increased slightly
during the study period, but by study







All 71.6 (59.3, 82.0) 82.6 (71.6, 90.7) 77.2 (69.2, 84.0)
Hypoglycemia symptoms 3.0 (0.4, 10.4) 2.9 (0.4, 10.1) 2.9 (0.8, 7.4)
Adverse drug reactions
All 6.0 (1.7, 14.6) 5.8 (1.6, 14.2) 5.9 (2.6, 11.3)
Hypoglycemia symptoms 3.0 (0.4, 10.4) 2.9 (0.4, 10.1) 2.9 (0.8, 7.4)
Data are incidence rate and 95% conﬁdence interval
DPP-4 dipeptidyl peptidase-4
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completion tended to return to baseline levels.
Blood pressure showed no significant changes
in either the DPP-4 inhibitor CTG or biguanide
CTG.
DISCUSSION
Mitiglinide, a rapid- and short-acting
insulinotropic agent, has been used to
improve postprandial hyperglycemia in T2DM
[11–13]. However, to date, sufficient evidence
has not been established for combined
treatment with a DPP-4 inhibitor or biguanide.
In this study, we investigated the efficacy and
safety of mitiglinide for use in combined
treatment in Japanese patients with T2DM
experiencing inadequate glycemic control with
DPP-4 inhibitors or biguanides monotherapy.
With regard to efficacy, in both the DPP-4
inhibitor CTG and biguanide CTG, the addition
of mitiglinide significantly stimulated early
postprandial insulin secretion, with significant
improvement in PPG (30 min, 1 h, and 2 h
values) throughout the study period. In
general, IGI is often B0.4 during a 75-g OGTT
in T2DM patients [14]. In this study, the
baseline IGI was as low as 0.15–0.17 (median
value), but after mitiglinide administration
many patients had an IGI C0.4 during a
400-kcal meal tolerance test. These results
confirmed an improvement in early
postprandial insulin secretion, a characteristic
of mitiglinide, even in combined treatment
with a DPP-4 inhibitor or biguanide.
A meal tolerance test to evaluate PPG values is
time consuming for patients and requires frequent
collection of blood samples. Therefore, when
compared with HbA1c and FPG, testing for PPG
is performed in few patients. However, glycemic
control based on HbA1c as a marker alone may not
Table 6 Adverse events and adverse drug reactions with an incidence of C5%













n % n % n % n %
Bronchitis 2 3.0 8 11.6 0 0.0 0 0.0
Nasopharyngitis 17 25.4 30 43.5 0 0.0 0 0.0
Pharyngitis 6 9.0 2 2.9 0 0.0 0 0.0
Upper respiratory tract inﬂammation 5 7.5 5 7.2 0 0.0 0 0.0
Dental caries 0 0.0 4 5.8 0 0.0 0 0.0
Arthralgia 4 6.0 1 1.4 0 0.0 0 0.0
Back pain 4 6.0 1 1.4 0 0.0 0 0.0
Alanine aminotransferase increase 0 0.0 5 7.2 0 0.0 0 0.0
c-glutamyltransferase increase 4 6.0 7 10.1 0 0.0 1 1.4
Blood urine present 0 0.0 4 5.8 0 0.0 0 0.0
White blood cell count increase 3 4.5 5 7.2 0 0.0 0 0.0
DPP-4 dipeptidyl peptidase-4
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reduce the incidence of macrovascular
complications [4–6]. To manage high-quality
glycemic control in T2DM patient, it is necessary
once again to recognize the clinical importance of
improving postprandial hyperglycemia.
Regarding HbA1c as a marker of overall
glycemic control, an HbA1c of \7.0% has been
established as a target in terms of preventing
diabetic complications [14]. In this study, at the
time of final evaluation, the HbA1c \7.0%
Fig. 4 Change in weight (mean ± SD). Top DPP-4 inhibitor combined treatment group. Bottom biguanide combined
treatment group
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achievement rate was 57.4% in the DPP-4
inhibitor CTG and 29.2% in the biguanide
CTG. Although this rate was somewhat low in
the biguanide CTG when compared with the
DPP-4 inhibitor CTG, the addition of
mitiglinide enabled a certain amount of
patients to reach this target goal.
In both the DPP-4 inhibitor CTG and
biguanide CTG, HbA1c transiently increased
after week 28, reached a peak at week 40, and
then again improved. The reason was probably
a seasonal fluctuation in HbA1c levels, as
clinically reported in Japan and overseas [12–
14]. These clinical reports have described
increased HbA1c levels from the autumn to
before spring, with fluctuations of about
0.2–0.3%. In this study, weeks 24–40 in many
patients corresponded to the period from
autumn to before spring. Considering that the
increase in HbA1c was also about 0.2–0.3%, the
fluctuation in this study was probably similar to
the seasonal fluctuations reported elsewhere
[15–17]. These findings again highlight the
importance of not only drug therapy, but also
dietary and exercise therapy in T2DM.
With regard to safety, the incidence of
hypoglycemia, which is generally a concern
when using oral glucose-lowering drugs, was
3.0% (2/67 patients) in the DPP-4 inhibitor CTG
and 2.9% (2/69 patients) in the biguanide CTG.
Thus, the incidence of hypoglycemia was low,
and all hypoglycemic symptoms were mild.
Body weight increased slightly during the
study in both the DPP-4 inhibitor CTG and
biguanide CTG, but by completion of treatment
tended to revert to baseline levels. This may also
be a seasonal fluctuation similar to glycemic
control.
This study has two important limitations.
Firstly, it was conducted under open label
design with no control arm, and therefore it
was not possible to eliminate all confounding
factors. Secondly, in our study, the variety of
DPP-4 inhibitors and biguanides used was
limited; the DPP-4 inhibitors were sitagliptin,
alogliptin and vildagliptin only, and biguanide
buformin was used in only three cases.
Therefore, interpretation of our findings
requires caution until further studies can be
conducted.
CONCLUSION
The combination of mitiglinide with DPP-4
inhibitors or biguanides improved
postprandial hyperglycemia and HbA1c, as a
marker of overall glycemic control, without
increasing risk to safety. This therapy is a
clinically promising therapeutic strategy for
T2DM.
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